Our top ten real-world considerations for managing heat intolerance in NMOSD.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng ™(satralizumab-mwge)…
The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult…
Dear Friends, We’re writing with heavy hearts to inform you that we have made the difficult decision to postpone our 12th Annual International Roundtable Conference…
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS)… Click here…
September 12, 2019 | Beverly Hills, CA — Genentech, a member of the Roche Group, announced positive results from one of its phase III clinical…
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)…
The past year has marked exciting advances in the world of NMO. From conferences to clinical trials, the foundation is pleased to share the latest…
October 23, 2018 | Beverly Hills, CA — Chugai Pharmaceutical Co. announced positive results from one of its phase III clinical trials of satralizumab (SA237),…
The Guthy-Jackson Charitable Foundation is pleased to welcome Christopher Clinton Conway in the newly-created position of Executive Director. Mr. Conway will serve as a highly-visible…
August 1, 2018, marks The Guthy-Jackson Charitable Foundation’s 10 Years Anniversary! In 2008, Ali Guthy, daughter of Victoria Jackson, founder & CEO of Victoria Jackson…
April 26, 2018 – Vatican City – Victoria Jackson, Founder of The Guthy-Jackson Charitable Foundation (GJCF), was honored with the 2018 Pontifical Key Advocacy Award…
Fast Facts about NMOSD
